The primary benefit of adavosertib is its ability to selectively target cancer cells with defective DNA repair mechanisms. This selectivity can potentially lead to more effective treatments with fewer side effects compared to traditional therapies. Furthermore, adavosertib can enhance the efficacy of existing treatments by sensitizing cancer cells to DNA-damaging agents.
